Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia

Inclusion criteria

• Able to understand and sign an informed consent form.

Exclusion criteria

• Women who are of childbearing potential.
• Very low likelihood of coronary artery disease (by American Heart Association and American College of Cardiology standards).
• Documented history of acute myocardial infarction within 30 days.
• Percutaneous coronary intervention or coronary bypass graft surgery within 3 years, unless typical or atypical anginal symptoms are present.
• Reactive airway disease or other contraindication that preclude a patient from receiving adenosine.
• Previous heart transplant or listed to receive a heart transplant.
• Cardiomyopathy (idiopathic dilated, restrictive, hypertrophic).
• History of hemodynamically significant supraventricular tachycardia or sustained ventricular tachycardia.
• Presence of second- or third-degree AV block (in the absence of permanent pacemaker).
• Left ventricular ejection fraction greater than 35%, known prior to the first imaging procedure.
• Presence of advanced heart failure, New York Heart Association Class IV.
• History of vasospastic/Prinzmetal angina.
• Active (under treatment) cancer (except skin cancers).
• Inability to discontinue antianginal medications, Aggrenox®, dipyridamole, and xanthine-containing drugs and foods (including caffeine) as required prior to each imaging procedure.
• Previous participation in a study of binodenoson.
• Any physical or psychosocial condition that, based on the Investigator's judgment, would prevent the patient from completing the study.